Effect of Rifampin on Vonoprazan PK in Healthy Volunteers

Phase 1, open-label, single-arm trial of vonoprazan in erosive esophagitis (EE), Helicobacter pylori infection and gastroesophageal reflux disease (GERD), sponsored by Phathom Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve from Time 0 to the Last Quantifiable Concentration at Day 17, Area Under the Plasma Concentration Versus Time Curve from Time 0 Extrapolated to Infinity at Day 17 and 1 more. Planned start Sep 2020; status: withdrawn.